AU9805398A - Novel human egf receptors and use thereof - Google Patents

Novel human egf receptors and use thereof

Info

Publication number
AU9805398A
AU9805398A AU98053/98A AU9805398A AU9805398A AU 9805398 A AU9805398 A AU 9805398A AU 98053/98 A AU98053/98 A AU 98053/98A AU 9805398 A AU9805398 A AU 9805398A AU 9805398 A AU9805398 A AU 9805398A
Authority
AU
Australia
Prior art keywords
novel human
human egf
egf receptors
receptors
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU98053/98A
Inventor
Gabriel Corfas
Klaus Elenius
Michael Klagsbrun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Medical Center Corp
Original Assignee
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center Corp filed Critical Childrens Medical Center Corp
Publication of AU9805398A publication Critical patent/AU9805398A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU98053/98A 1997-10-15 1998-10-15 Novel human egf receptors and use thereof Abandoned AU9805398A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6237397P 1997-10-15 1997-10-15
US60062373 1997-10-15
PCT/US1998/021828 WO1999019488A1 (en) 1997-10-15 1998-10-15 Novel human egf receptors and use thereof

Publications (1)

Publication Number Publication Date
AU9805398A true AU9805398A (en) 1999-05-03

Family

ID=22042059

Family Applications (1)

Application Number Title Priority Date Filing Date
AU98053/98A Abandoned AU9805398A (en) 1997-10-15 1998-10-15 Novel human egf receptors and use thereof

Country Status (2)

Country Link
AU (1) AU9805398A (en)
WO (1) WO1999019488A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01013240A (en) 1999-06-25 2002-06-21 Genentech Inc METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES.
SI1189641T1 (en) 1999-06-25 2009-12-31 Genentech Inc HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
US6627196B1 (en) 1999-08-27 2003-09-30 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
KR101135233B1 (en) 2000-05-19 2012-04-12 제넨테크, 인크. Gene Detection Assay for Improving the Likelihood of an Effective Response to an ErbB Antagonist Cancer Therapy
AUPQ841800A0 (en) * 2000-06-28 2000-07-20 Biomolecular Research Institute Limited Truncated egf receptor
US6255111B1 (en) 2000-07-31 2001-07-03 Isis Pharmaceuticals, Inc. Antisense modulation of Her-4 expression
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
PT2263691E (en) 2002-07-15 2012-11-12 Hoffmann La Roche Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2c4 (rhumab 2c4)
EP2286844A3 (en) 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
WO2006034488A2 (en) 2004-09-23 2006-03-30 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US7939267B2 (en) 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
TWI441646B (en) 2005-01-21 2014-06-21 Genentech Inc Use of pertuzumab in the manufacture of a medicament for treating cancer in a human patient
ES2440481T3 (en) 2005-02-23 2014-01-29 Genentech, Inc. Time extension until disease progression or survival in ovarian cancer patients using pertuzumab
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
ES2417148T3 (en) 2007-06-08 2013-08-06 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
MX2011004050A (en) * 2008-10-17 2011-05-10 Genentech Inc Treatment method.
CA2744512C (en) * 2008-11-25 2018-05-15 Genentech, Inc. Isoform specific anti-her4 antibodies
CN104447995A (en) 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 Bispecific anti-HER antibodies
BR112012012983A2 (en) 2009-12-04 2020-09-15 Genentech Inc method of synthesizing a multispecific antibody, method of synthesizing a panel of multispecific antibodies, method of synthesizing an antibody analog, method of synthesizing a panel of antibody analogs and compositions
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
ME02637B (en) 2010-08-20 2017-06-20 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
CN104024432B (en) 2011-08-31 2017-02-22 基因泰克公司 Diagnostic Markers
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
CN104159924B (en) 2011-12-05 2018-03-16 诺华股份有限公司 The antibody of EGF-R ELISA 3 (HER3)
JP2015514710A (en) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Diagnosis and treatment of HER3 inhibitors
RU2016141385A (en) 2014-03-24 2018-04-28 Дженентек, Инк. CANCER TREATMENT WITH C-MET ANTAGONISTS AND THEIR CORRELATION WITH HGF EXPRESSION
ES2729202T3 (en) 2014-07-16 2019-10-30 Dana Farber Cancer Inst Inc Et Al Inhibition of HER3 in low grade serous ovarian cancers
EP3615695A1 (en) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2 mutations in the transmebrane or juxtamembrane domain

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2202533A1 (en) * 1994-10-14 1996-04-25 Bristol-Myers Squibb Company Her4 human receptor tyrosine kinase

Also Published As

Publication number Publication date
WO1999019488A1 (en) 1999-04-22
WO1999019488A9 (en) 1999-06-03
WO1999019488A8 (en) 1999-10-14

Similar Documents

Publication Publication Date Title
AU9805398A (en) Novel human egf receptors and use thereof
AU5752398A (en) Novel ketobenzamides and their use
AU694696B2 (en) Sulfonamides and their use
AU3728197A (en) Human telomerase
AU7718898A (en) Txu-7-pap immunotoxin and use thereof
AU6030398A (en) Human proteins
AU8905098A (en) Skin care compositions and use
AU9781998A (en) Huchordin and uses thereof
AU4266596A (en) Composition and use
AU1926000A (en) Pth1r and pth3r receptors
AU1968400A (en) Human vanilloid receptors and their uses
GB9717598D0 (en) Novel composition and use
AU1592099A (en) Skin care composition
AU4522796A (en) Human somatostatin-like receptor
AU8815298A (en) Improvements relating to surgical devices and their location
AU3634595A (en) Bis-oxazolidines and their use
AU9017598A (en) Human frezzled-like protein
AU5918598A (en) Human extracellular matrix-1
AU6035398A (en) Human c5a-like receptor
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
AU3116697A (en) Human interleukin-1j and antagonists thereof
AU5763098A (en) Arylthio-dithiazindioxides and their use as pesticides
AU8019494A (en) Human endothelin-bombesin receptor
HUP9800247A3 (en) Promoter for human endoglingene and its use
AU1645599A (en) Human matrilin-3

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase